So anyway, at this pps companies rarely have any revenue,

New Post Public Reply Private Reply Replies (2) Message Board
microcaps microcaps #452

So anyway, at this pps companies rarely have any revenue, let alone any net income. I've seen stocks as high as 50 dollars plus pps w large NEGATIVE income. The Penny world-like quantum physics -is strange-their pps (as low as it is) is usually astonomical compared to income-  w equivalent PE's -based on future SPECULATIVE income of 20-1000 plus. How do u figure the ratio when the income is negative-I've seen pennies as high as 1 dollar/share w book value as low as a negative 15 dollars-meaning each share is worth negative 15 dollars in real world "assets"otherwise known as liabilities. One company had 50 million in debt and only 5k in assets and had uplisted to OTCQB-how?

Cf that to CWRN-which, including inventory-could have a net assets/stockholders equity as high as 30 million.

4.361 B shares O/S divided into the guess of 10 million net income(see previous post) is .002293052 net income/share.

So at a PE of 15 that would be a pps of 3.44c; a PE of 20 would yield a pps of 4.586c

Current pps of .0039 yields a market cap of 17 million-which is less than the inventory is worth!

.0039 is only 1/10.256 of what should be a 4c pps (at ca a PE of 17.5) and thus assumes CWRN only has 10 million dollars divided by 10.256 or 975,000 net income-and ignores future income -which should be several times greater -as we have seen from huge mine expansion and millions in additional equipment plus coming ancillary income streams

Note CWRN pps had risen as high as 3.1c before first ship -before any revenue=and is now only 1/8 of that pps-at .0039. When you finally find a rare penny co breakthrough like CWRN and yet pps falls like this -its a twilight zone world-and answer is to file current financials and uplist to ecape this bizarre world-unless big investors realize how undervalued this is.

the iron ore business is known for its current high profit margin-as I said spot is public knowledge and so is average jr miners cost-so most jr miners have a profit margin exceeding 50%. Some have negative cost due to premium ore -even without CWRN's coming ancillary income streams

Remember these pennies probably have a SPECULATIVE FUTURE income equivalent average PE of ca 50-then once co's have net income the parallel universe of pennytraders punishes them-I have yet to understand the logic-especially when most of these low priced pennies never achieve net income and fail.

There are many reasons which we are aware of-games by otc/dtc/mm/brokers/shorters/restrictions by brokers- they say because pps is below 1c and no current posted financials. Without current posted financials many brokers restrict buying as part of a new effort starting in 2011 to eliminate low priced pennies and many potential buyers have been standing on the sidelines waiting for posted financials before buying- and the improperly imposed by non regulatory for profit otc classification(based on shorters shout fire of a promotion which never occurred) is also a large drag. So we await the promised uplisting w its audited financials.

Cotton & Western Mining Inc. (CWRN) Stock Research Links

CWRN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Driven Tech Lands on 2026 CRN AI Innovators List

Updated Category News Views 4

New Milestone for Driven Tech in AI Innovation If there's one thing that's becoming crystal clear in the tech world, it's this: AI isn't just a flashy add-on anymore. Companies are diving deep into AI waters, transforming their business strategies from the ground up. Driven Tech, Inc., is doing just that, and their efforts haven't gone unnoticed—they’ve made it onto...

Continue Reading
Clarivate Taps Global Appetite for AI Research Tools

Updated Category News Views 8

A Growing Global Thirst for AI-Enhanced Research It looks like the folks at Clarivate have struck a chord. Their Web of Science Research Intelligence platform is garnering attention across the globe, embraced by more than 100 institutions spanning 25 countries. When you craft something that taps into a core need, well, people will jump on it—and that's exactly what's...

Continue Reading
PKGD Group's Agave Spirits Surge 56% in 2026 Growth'

Updated Category News Views 1

PKGD Group's Impressive Growth Story Sometimes you read a report and it genuinely knocks the wind out of you—not because it’s unusual, but because it’s rare to see such robust numbers in a market that ain't exactly all sunshine and rainbows. PKGD Group, the brain behind some damn fine agave spirits, decided to take no prisoners this year, reporting a jaw-dropping...

Continue Reading
ELEGOO's M1 Ultra: Bridging Gap in 3D Scanning Tech

Updated Category News Views 3

A Leap in 3D Scanning: Say Hello to M1 Ultra ELEGOO isn't just fiddling with a toy here—this Shenzhen-based juggernaut is rolling out the M1 Ultra on October 29, 2026, and it's causing quite a stir. While the stock market doesn't see immediate tremors from every shiny new gadget, there’s something to say when a company that pulled over $300 million in sales last year...

Continue Reading
Rznomics Advances with EU Orphan Status for RZ-001

Updated Category News Views 3

RZ-001's European Success: A New Frontier Look, when a biopharmaceutical firm's RNA-editing therapy snags an Orphan Medicinal Product Designation from the European Commission, it's not just some clipboard milestone—it's a heavy-hitter move. That's exactly what Rznomics, the South Korean gene therapy player, pulled off with RZ-001. Now, we aren't just seeing paperwork...

Continue Reading
Durabook R12 Tablet: A Rugged Revolution for AI Tasks

Updated Category News Views 7

Edge AI Gets a Rugged Boost with Durabook's R12 In a world teeming with tech gadgets that crumble at the first sign of a challenge, Durabook's R12 Rugged Tablet makes a solid entrance. This ain't your everyday pretty gadget. Think of it as the big, burly bodyguard of tablets, ready to box through harsh environments without dropping a pixel. What’s stirring the pot this...

Continue Reading
When Families Should Consider Life Insurance Plans

Updated Category News Views 0

Let’s talk about why life insurance isn’t just for those walking around with gray hair. K.D. the Insurance Queen from Centennial, Colorado, dishes out the clearest advice on when and why families ought to have it in their arsenal. A New Mindset on Life Insurance Some folks out there think life insurance is something you ponder in your twilight years. But here’s the...

Continue Reading
Hims & Hers Faces Class Action: Investor Implications

Updated Category News Views 6

Serious Scrutiny for Hims & Hers There's trouble in paradise, folks. Hims & Hers Health, Inc. (NYSE: HIMS) just landed in hot water, and it's not the soothing kind. We're talking about allegations of privacy violations and deceptive practices that have sent ripples—or more like waves—across the investor pond. If you're holding shares, you've probably felt the jolt...

Continue Reading
UMC and AP Memory Boost Power with New AI Chips

Updated Category News Views 4

Breaking Ground in Data Center Power Every so often, the tech industry gets a jolt of innovation that turns heads—not just for what it can do today, but for what it promises tomorrow. This time, it's United Microelectronics Corporation (UMC) and AP Memory shaking things up with their collaboration aimed at redefining power delivery for AI and high-performance computing...

Continue Reading
AuraQuantic Leads SPARK Matrix™ in 2026 IPO Ranking

Updated Category News Views 2

Not Just Another Day in Tech When tech outfits make headlines, it's often because of a shiny new gadget or some jarring security breach. Today, it's AuraQuantic getting their well-deserved spotlight, having snagged the leader's spot in the SPARK Matrix™ for Intelligent Process Orchestration (IPO). You might be wondering what makes this accolade worth attention in a...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Atlassian's Recent Options Activity Surge

Updated Category News Views 163

Analyzing Atlassian's Options Activity Recently, significant activity has been noted in the options market for Atlassian (NASDAQ: TEAM), suggesting fluctuating sentiment among investors. With several key trades occurring, it is vital to understand the underlying forces driving these changes. Insights from Options Trading An examination of options history indicates that a...

Continue Reading
Oncolytics Biotech's Strategic Move to Lead Cancer Innovation

Updated Category News Views 176

Oncolytics Biotech's Strategic Move to Lead Cancer Innovation In a time where the global oncology drug market is projected to exceed an astounding $900 billion, interest in cancer-focused biotechnology companies has surged significantly. Analysts highlight the increasing demand for innovative diagnostics and advanced immunotherapies driving this growth. Yet, as these...

Continue Reading
Transformations in Admirals Group AS Leadership and Governance

Updated Category News Views 170

Changes in Leadership at Admirals Group AS Admirals Group AS recently held a significant general meeting where key changes to its management and supervisory boards were decided. Effective from a stated future date, Anton Tikhomirov and Fedor Ragin have been appointed to the supervisory board for a term of five years. This shift marks an exciting new chapter in the...

Continue Reading
Athens Stock Market Reaches New Heights with Gains

Updated Category News Views 175

Athens Stock Market Performance Overview The latest updates reveal that Greece's stock market has closed on a positive note, showcasing notable increases across various sectors. The Athens General Composite Index has gained traction, finishing higher as key market sectors, particularly Construction, Travel, and Banking, experienced substantial growth. Sectorwise...

Continue Reading
Johnson & Johnson's Tremfya Shows Promising Results for Crohn's Disease

Updated Category News Views 227

Introduction to Tremfya and Crohn's Disease Tremfya, a medication developed by Johnson & Johnson, has gained notable attention for its role in treating Crohn's disease. Recently, new results from its Phase 3 GRAVITI study have sparked interest in its potential expanded usage, showing promising outcomes for patients. Exciting Results from the GRAVITI Study The GRAVITI...

Continue Reading